Sunitinib News and Research RSS Feed - Sunitinib News and Research

Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). It is used in patients whose condition has become worse while taking another drug called imatinib mesylate or who are not able to take imatinib mesylate.
New drug provides considerable added benefit in treating adults with advanced renal cell cancer

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy. [More]
Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Watch-and-wait approach means some patients could delay taking highly toxic non-curative anticancer drugs that come with substantial side effects [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Popular kidney cancer drugs do not reduce incidence of recurrence

Popular kidney cancer drugs do not reduce incidence of recurrence

Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to a new multi-institutional study in the Lancet led by a researcher at the Abramson Cancer Center (ACC) of the University of Pennsylvania. [More]
Therapy change significantly improves treatment outcomes for renal cell carcinoma patients

Therapy change significantly improves treatment outcomes for renal cell carcinoma patients

A research team of the Comprehensive Cancer Center of MedUni Vienna and AKH Vienna was able to demonstrate that a therapy change in the area of metastasising renal cell carcinoma significantly increases the life average expectancy and clearly improves the compatibility of the therapy. [More]
Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib offers significantly longer progression-free survival than everolimus for patients with metastatic non-clear cell renal cell carcinoma, phase II trial results indicate, but treatment effect appears to depend upon key patient characteristics. [More]
Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract. [More]
Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012) in the United States. [More]
New clinical trial uses aggressive treatment method for patients with pancreas cancer

New clinical trial uses aggressive treatment method for patients with pancreas cancer

Pancreas cancer remains one of the deadliest cancers worldwide. In the United States, it accounts for only three percent of all diagnosed cancers but it causes almost seven percent of all cancer deaths. A pancreas cancer diagnosis often comes after age 50 and after the cancer has spread, making it difficult to remove surgically. [More]
Poorly-designed animal study threatens validity of preclinical research

Poorly-designed animal study threatens validity of preclinical research

Badly designed studies may lead to the efficacy of drugs being overestimated and money being wasted on trials that prove fruitless, according to new a study from McGill University in Canada. [More]
Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that function as an "on" or "off" switch in many cellular processes, including cancer. [More]
Tolerability benefits with sunitinib schedule switch

Tolerability benefits with sunitinib schedule switch

Switching sunitinib treatment from a 4/2 to a modified 2/1 schedule can improve the tolerability profile for patients with metastatic renal cell carcinoma, say researchers. [More]
First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

In metastatic renal cell carcinoma patients, there is no significant correlation between adverse event profiles of first- and second-line tyrosine kinase inhibitors, suggests a Japanese study. [More]
Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma. [More]
IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced an independent data monitoring committee (IDMC) has recommended the continuation of the company’s pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) following the first of three planned interim data analyses. [More]
Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14. [More]
‘Real-world’ sunitinib findings support trial results

‘Real-world’ sunitinib findings support trial results

Results of postmarketing follow-up in Japanese patients confirm the efficacy and safety profile of sunitinib in advanced renal cell carcinoma. [More]
SNPs predict sunitinib outcome in mRCC

SNPs predict sunitinib outcome in mRCC

Research has confirmed that single nucleotide polymorphisms in genes related to the processing of sunitinib influence the outcome of treatment for metastatic renal cell carcinoma. [More]
RCC benefit independent of sorafenib, sunitinib sequence order

RCC benefit independent of sorafenib, sunitinib sequence order

Sequential treatment with sorafenib followed by sunitinib is not superior to sunitinib followed by sorafenib in patients with advanced or metastatic renal cell carcinoma, suggests research published in European Urology. [More]
Study compares effectiveness of treatments for metastatic non-clear cell kidney cancers

Study compares effectiveness of treatments for metastatic non-clear cell kidney cancers

A head-to-head comparison of two biologic therapies used to treat a subset of patients with advanced kidney cancers provides much-needed clarity on the preferred treatment for the first line of attack. [More]
Advertisement
Advertisement